2008P Assessing response durability and survival after second-line pembrolizumab in advanced urothelial carcinoma: A multicenter validation of a risk model. - Salah, S.; Kobayashi, T.; Ito, K.; Kita, Y.; Horani, M.; Alshangiti, A.; Abu Hijlih, R.; Sammour, M.; Abuhijla, F.; Al-Rabi, K. (Annals of Oncology, 2024)